Details of the Drug

General Information of Drug (ID: DMBH4FL)

Drug Name
BI 655066
Indication
Disease Entry ICD 11 Status REF
Chronic plaque psoriasis EA90.0 Phase 3 [1]
Ankylosing spondylitis FA92.0 Phase 2 [2]
Crohn disease DD70 Phase 2 [1]
Psoriatic arthritis FA21 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0A0MS
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic plaque psoriasis
ICD Disease Classification EA90.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-23 (IL23) DTT IL23A 5.37E-01 -0.1 -0.42
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02443298) Efficacy and Safety of BI 655066 in Patients With Severe Persistent Asthma.. U.S. National Institutes of Health.
3 Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.